1. Carillon S, Girard G. Mieux comprendre les défis de la médicalisation de la prévention du VIH en France : la prophylaxie préexposition au prisme des sciences sociales. Glob Health Promot. 2020;27(2):149–53.
2. Young I, Calliste J. PrEP and women in Scotland roundtable: a community report [Internet]. 2018 [cited 2022 Oct 26]. Available from: https://www.ed.ac.uk/usher/biomedicine-self-society/news-events/news/prep-and-women
3. Scott HM, Spinelli M, Vittinghoff E, Morehead-Gee A, Hirozawa A, James C, et al. Racial/ethnic and HIV risk category disparities in preexposure prophylaxis discontinuation among patients in publicly funded primary care clinics. AIDS. 2019;33(14):2189–95.
4. Sasse A, Deblonde J, de Rouck M, Montourcy M, van Beckhoven D. Epidemiologie van aids en hiv-infectie in België. Toestand of 31 december 2018. [Internet]. 2019 [cited 2022 Oct 26]. Available from: https://www.sciensano.be/nl/biblio/epidemiologie-van-aids-en-hiv-infectie-belgie-toestand-31-december-2018
5. Sasse A, Deblonde J, de Rouck M, Montourcy M, van Beckhoven D. Epidemiologie van AIDS en hiv-infectie in België. Toestand op 31 december 2019 [Internet]. 2020 [cited 2022 Jun 24]. Available from: https://www.sciensano.be/en/biblio/epidemiologie-van-aids-en-hiv-infectie-belgie-toestand-op-31-december-2019